Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24


51061 items
1:02 PM, Jun 20, 2018  |  BC Extra | Company News

TG, Novimmune developing CD47/CD19 bispecific

TG Therapeutics Inc. (NASDAQ:TGTX) partnered with Novimmune S.A. (Plan-les-Ouates, Switzerland) to develop Novimmune’s TG-1801 (formerly NI-1701). The companies plan to begin clinical testing of the candidate this year or early next year, with a focus...
12:50 PM, Jun 20, 2018  |  BC Extra | Company News

FDA panel to review Paratek antibiotic

FDA's Antimicrobial Drugs Advisory Committee has scheduled an Aug. 8 meeting to discuss two NDAs for omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The agency is reviewing oral and IV versions of the amniomethylcycline antibioitic to treat...
11:45 AM, Jun 20, 2018  |  BC Extra | Financial News

Galmed raises $75M follow-on

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) raised $75 million through the sale of 5 million shares at $15 in a follow-on underwritten by Stifel, SunTrust Robinson Humphrey, Cantor Fitzgerald, Raymond James, Roth Capital Partners, Maxim Group and...
7:24 AM, Jun 20, 2018  |  BC Extra | Financial News

Aminex raises $10M, starts Phase I cancer trial

Aminex Therapeutics Inc. (Seattle, Wash.) raised $10 million in an untranched series B round. The company declined to name its investors. The company said Wednesday that it dosed the first patient in a Phase I trial...
7:15 AM, Jun 20, 2018  |  BC Extra | Financial News

Eidos gets first-day bump after pricing IPO at top of range

Eidos Therapeutics Inc. (NASDAQ:EIDX) added $6.12 (36%) to $23.12 Wednesday after raising $106.3 million through the sale of 6.3 million shares at $17 in an IPO underwritten by J.P. Morgan, BofA Merrill Lynch and Barclays....
6:53 PM, Jun 19, 2018  |  BC Extra | Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) was off $9.62 (21%) to $36.50 in after-hours trading Tuesday after reporting that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with OA of...
6:47 PM, Jun 19, 2018  |  BC Extra | Financial News

Oncology play iTeos raises $75M, outlines clinical plans

iTeos Therapeutics S.A. (Gosselies, Belgium) raised $75 million in a series B round led by MPM Capital. Also participating in the round were HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI as well as...
6:45 PM, Jun 19, 2018  |  BC Extra | Preclinical News

Antibody selection method improves on phage display

A team at The Scripps Research Institute has developed a method to screen for functional antibodies that improves on standard phage display and incorporates functionality testing in one step. Principal investigator Richard Lerner told BioCentury the...
3:47 PM, Jun 19, 2018  |  BC Extra | Politics & Policy

National Academies recommends defense strategies against biosynthetic weapons

While synthetic biology could be weaponized, similar technology could be used to mitigate those potential threats, concludes a report released Tuesday by the National Academies of Sciences, Engineering, and Medicine (NASEM). In the report, NASEM identified...
3:40 PM, Jun 19, 2018  |  BC Extra | Company News

UC Regents issued CRISPR-Cas9 guide RNA patent in U.S.

The U.S. Patent Office on Tuesday granted a patent related to CRISPR-Cas9 gene editing technology to the Regents of the University of California, the University of Vienna and Emmanuelle Charpentier covering use of guide RNA...